Ferrer et al. analyzed 48 patients with EGFR-mutant NSCLC and 13 with non–EGFR-mutant who had developed small cell transformation and 45% of the patients with EGFR-mutant and 40% of non-EFGR-mutant patients achieved an objective response to platinum plus etoposide treatment [18]; however, Ho et al. put forward a different opinion. This evidence concerns the gene EGFR and non-small cell lung carcinoma.